statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Oncolytics Biotech Reports First Quarter 2024 Financial Results and Operational Highlights Oncolytics Biotech Reports First Quarter 2024 Financial Results and Operational Highlights PR Newswire SAN...

Oncolytics Biotech Reports First Quarter 2024 Financial Results and Operational Highlights

Fight Against Pancreatic Cancer Ramps Up as Market Size Revenues Expected to Exceed $36 Billion by 2036 Fight Against Pancreatic Cancer Ramps Up as Market Size Revenues Expected to Exceed $36 Billion...

Fight Against Pancreatic Cancer Ramps Up as Market Size Revenues Expected to Exceed $36 Billion by 2036

Biotech Innovations Surge as Global Cancer Diagnosis Rates Continue to Climb Biotech Innovations Surge as Global Cancer Diagnosis Rates Continue to Climb PR Newswire VANCOUVER, BC, May 9, 2024 USA...

Biotech Innovations Surge as Global Cancer Diagnosis Rates Continue to Climb

Oncolytics Biotech Receives Regulatory Clearance to Evaluate Pelareorep in Combination with Modified FOLFIRINOX +/- an anti-PD-L1 Inhibitor in Pancreatic Cancer Oncolytics Biotech Receives Regulatory...

Oncolytics Biotech Receives Regulatory Clearance to Evaluate Pelareorep in Combination with Modified FOLFIRINOX +/- an anti-PD-L1 Inhibitor in Pancreatic Cancer

Oncolytics Biotech to Participate in a Fireside Chat at the 2024 RBC Capital Markets Global Healthcare Conference Oncolytics Biotech to Participate in a Fireside Chat at the 2024 RBC Capital Markets...

Oncolytics Biotech to Participate in a Fireside Chat at the 2024 RBC Capital Markets Global Healthcare Conference

Top Five Cancer Types Dominate New US Cases as Biotech Sector Eyes $314B Market by 2032 Top Five Cancer Types Dominate New US Cases as Biotech Sector Eyes $314B Market by 2032 PR Newswire VANCOUVER...

Top Five Cancer Types Dominate New US Cases as Biotech Sector Eyes $314B Market by 2032

As Early-Onset Breast Cancer Cases Soar in North America and EU, Biotech Ramps Up Response As Early-Onset Breast Cancer Cases Soar in North America and EU, Biotech Ramps Up Response PR Newswire...

As Early-Onset Breast Cancer Cases Soar in North America and EU, Biotech Ramps Up Response

Oncolytics Biotech to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights Oncolytics Biotech to Host Conference Call to Discuss First Quarter Financial...

Oncolytics Biotech to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights

Oncolytics Biotech Announces Upcoming Presentations at the American Society of Clinical Oncology Annual Meeting Oncolytics Biotech Announces Upcoming Presentations at the American Society of Clinical...

Oncolytics Biotech Announces Upcoming Presentations at the American Society of Clinical Oncology Annual Meeting

Oncolytics Biotech, Inc. engages in the development of immuno-oncolytic virus for the treatment of solid tumors and hematological malignancies. It offers a non-pathogenic, properietary isolate of the reovirus that induce selective tumor lysis, and promotes an inflamed tumor phenotype through innate and adaptive immune responses. The company was founded by Matthew C. Coffey and Bradley George Thompson on April 2, 1998 and is headquartered in Calgary, Canada.

Watchers	6,986
52-Wk Low	$0.883
52-Wk High	$3.39

Volume	93,646.00
52-Wk High	$3.39
52-Wk Low	$0.883

Period	Estimated	Reported	Surprise	Result
Q2'24	-$0.08	--	--	N/A
Q1'24	-$0.08	-$0.07	21.06%	BEAT
Q4'23	-$0.11	-$0.04	65.55%	BEAT
Q3'23	-$0.08	-$0.10	-29.74%	MISSED
Q2'23	-$0.09	-$0.09	-1.10%	MISSED

ONCY Oncolytics Biotech, Inc.

About

Feed

News

Earnings

Fundamentals